

# Dimitrios Patoulas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5697789/publications.pdf>

Version: 2024-02-01

139  
papers

567  
citations

758635

12  
h-index

887659

17  
g-index

139  
all docs

139  
docs citations

139  
times ranked

836  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pseudohyperaldosteronism due to mumijo consumption during pregnancy: a licorice-like syndrome. <i>Gynecological Endocrinology</i> , 2024, 34, 1019-1021.	0.7	13
2	Correspondence on "Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e195-e195.	0.5	2
3	Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. <i>Acta Cardiologica</i> , 2023, 78, 519-524.	0.3	9
4	Shockwave Coronary Intravascular Lithotripsy System for Heavily Calcified De Novo Lesions and the Need for a Cost-Effectiveness Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2022, 37, 128-134.	0.3	9
5	Colchicine for the prevention of COVID-19 "hard" outcomes: All that glitters is not gold. <i>European Journal of Internal Medicine</i> , 2022, 97, 108-109.	1.0	0
6	Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2022, 165, 133-135.	0.7	2
7	Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?. <i>International Journal of Cardiology</i> , 2022, 348, 175.	0.8	0
8	OUP accepted manuscript. <i>British Journal of Surgery</i> , 2022, , .	0.1	0
9	Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
10	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. <i>American Journal of Cardiology</i> , 2022, 167, 165-167.	0.7	1
11	Epicardial adipose tissue: does it mediate the cardio"protective effects of sodium" glucose co"transporter 2 inhibitors in patients with heart failure? Letter regarding the article "Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure". <i>European Journal of Heart Failure</i> . 2022, 24, 400-401.	2.9	1
12	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with Type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. <i>Kardiologia Polska</i> , 2022, 80, 80-82.	0.3	0
13	Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2022, 37, 170-174.	1.3	2
14	Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106257.	0.7	4
15	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2022, 166, 144-145.	0.7	3
16	Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2022, 386, e17.	13.9	10
17	"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series" comment. <i>Internal and Emergency Medicine</i> , 2022, , .	1.0	0
18	Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
19	Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
20	“Which one should I choose, a glucagon-like peptide-1 receptor agonist or a sodium-glucose cotransporter 2 inhibitor? Or maybe both?” <i>European Journal of Internal Medicine</i> , 2022, 98, 125-127.	1.0	1
21	Meta-Analysis Addressing the Cardiovascular Safety of Daprodustat in Patients With Chronic Kidney Disease Undergoing Dialysis or Not. <i>American Journal of Cardiology</i> , 2022, 170, 166-167.	0.7	2
22	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2022, 173, 157-158.	0.7	6
23	Impact of Primary Aldosteronism in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2022, , 1.	1.5	2
24	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. <i>Kardiologia Polska</i> , 2022, 80, 696-698.	0.3	1
25	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease. <i>American Journal of Cardiology</i> , 2022, 174, 188-189.	0.7	1
26	Serum uric acid lowering mediated by glucagon-like peptide-1 receptor agonists: Emerging considerations. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4239-4239.	1.1	1
27	Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19. <i>American Journal of Cardiology</i> , 2022, 175, 185-187.	0.7	1
28	Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity. <i>American Journal of Cardiology</i> , 2022, 175, 182-184.	0.7	3
29	Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. <i>Vascular Medicine</i> , 2022, 27, 433-439.	0.8	8
30	Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2022, 178, 178-179.	0.7	4
31	SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 574-576.	0.7	2
32	Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. <i>Hepatology</i> , 2021, 73, 866-866.	3.6	1
33	Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?. <i>International Journal of Cardiology</i> , 2021, 323, 259.	0.8	1
34	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. <i>American Journal of Cardiology</i> , 2021, 138, 116-118.	0.7	1
35	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. <i>American Journal of Cardiology</i> , 2021, 139, 134-136.	0.7	1
36	Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. <i>American Journal of Cardiology</i> , 2021, 139, 139-141.	0.7	11

#	ARTICLE	IF	CITATIONS
37	Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101568.	0.7	6
38	Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1063-1065.	2.2	6
39	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging.. <i>American Journal of Cardiology</i> , 2021, 138, 129-132.	0.7	2
40	Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. <i>Acta Diabetologica</i> , 2021, 58, 125-126.	1.2	0
41	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. <i>Indian Heart Journal</i> , 2021, 73, 132-134.	0.2	3
42	All That Glitters is not Gold! A Case of Concomitant Acute Pericarditis and Subsegmental Pulmonary Embolism. <i>Mediterranean Journal of Rheumatology</i> , 2021, 31, 88.	0.3	0
43	A Patient with Rheumatoid Arthritis under Methotrexate and Etanercept Treatment Presenting with Fever and Pancytopenia: An Unexpected Guest. <i>Mediterranean Journal of Rheumatology</i> , 2021, 32, 160.	0.3	1
44	The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. <i>JAMA Surgery</i> , 2021, 156, 204.	2.2	2
45	The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression?. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 315-316.	0.3	0
46	The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. <i>Blood Pressure Monitoring</i> , 2021, 26, 284-287.	0.4	4
47	Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1696-1700.	2.2	4
48	Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?. <i>Kardiologia Polska</i> , 2021, 79, 360-360.	0.3	0
49	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. <i>Current Pharmaceutical Design</i> , 2021, 27, 1289-1297.	0.9	8
50	Testosterone levels in COVID-19: More data, but how do we proceed?. <i>Andrologia</i> , 2021, 53, e14088.	1.0	0
51	Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?. <i>International Journal of Cardiology</i> , 2021, 330, 228.	0.8	2
52	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. <i>European Journal of Internal Medicine</i> , 2021, 87, 100-101.	1.0	3
53	Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?. <i>American Heart Journal</i> , 2021, 236, 104-105.	1.2	1
54	Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2021, . .	0.1	0

#	ARTICLE	IF	CITATIONS
55	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. <i>Kidney Medicine</i> , 2021, 3, 674-675.	1.0	5
56	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. <i>Clinical Rheumatology</i> , 2021, 40, 4671-4674.	1.0	21
57	Cardiorespiratory fitness in kidney transplant recipients compared to patients with kidney failure: a systematic review and meta-analysis. <i>Transplant International</i> , 2021, 34, 1801-1811.	0.8	2
58	Hypertension in Pregnancy: Unanswered Questions. <i>Current Pharmaceutical Design</i> , 2021, 27, 3795-3803.	0.9	2
59	Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken?. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	1
60	Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma. <i>European Journal of Internal Medicine</i> , 2021, 90, 107-108.	1.0	4
61	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. <i>Endocrinology and Metabolism</i> , 2021, 36, 904-908.	1.3	21
62	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. <i>American Journal of Cardiology</i> , 2021, 159, 143-146.	0.7	5
63	Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 157, 150-152.	0.7	2
64	Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?. <i>Kardiologia Polska</i> , 2021, 79, 1048-1049.	0.3	0
65	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2021, , .	0.7	0
66	SGLT-2 Inhibitors Beneficial Effects on Ventricular Repolarization May Be Protective against Atrial Fibrillation Occurrence. <i>Acta Cardiologica Sinica</i> , 2021, 37, 323.	0.1	1
67	Glucagon-like peptide-1 receptor agonists do not decrease the risk of coronary revascularization in patients with type 2 diabetes. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, .	0.3	0
68	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. <i>American Journal of Cardiology</i> , 2021, 161, 120-122.	0.7	0
69	Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction. <i>Nefrologia</i> , 2021, , .	0.2	0
70	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2021, 161, 118-120.	0.7	2
71	Femoral artery thrombosis in an 11-year old boy due to a blunt trauma.. <i>Folia Medica Cracoviensia</i> , 2021, 61, 115-119.	0.3	0
72	Time to assess the effects of sodium-glucose co-transporter-2 inhibitors on the "forgotten" right ventricle?. <i>ESC Heart Failure</i> , 2020, 7, 334-335.	1.4	3

#	ARTICLE	IF	CITATIONS
73	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. <i>Digestive and Liver Disease</i> , 2020, 52, 239-240.	0.4	1
74	Sodium-Glucose Cotransporter-2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. <i>Diabetes Therapy</i> , 2020, 11, 3003-3005.	1.2	6
75	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 137, 130-132.	0.7	2
76	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. <i>American Journal of Cardiology</i> , 2020, 137, 133-135.	0.7	2
77	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2020, 134, 149-152.	0.7	4
78	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. <i>Journal of Human Hypertension</i> , 2020, 34, 764-767.	1.0	25
79	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1419-1429.	0.3	17
80	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. <i>Current Hypertension Reports</i> , 2020, 22, 90.	1.5	35
81	Sodium-glucose co-transporter-2 inhibitors and arterial stiffness: Class effect or drug effect?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 2389-2390.	1.0	2
82	Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 460-461.	0.8	0
83	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. <i>European Journal of Internal Medicine</i> , 2020, 77, 153-155.	1.0	5
84	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. <i>Journal of Clinical Hypertension</i> , 2020, 22, 562-571.	1.0	24
85	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and meta-analysis of randomized, sham-controlled, catheter-based trials. <i>Journal of Clinical Hypertension</i> , 2020, 22, 572-584.	1.0	29
86	Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. <i>Acta Diabetologica</i> , 2020, 57, 905-906.	1.2	0
87	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. <i>Current Vascular Pharmacology</i> , 2020, 18, 125-138.	0.8	9
88	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 347.	1.8	1
89	Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. <i>Diabetes and Metabolism</i> , 2020, 46, 272-279.	1.4	9
90	Hitting two birds with one stone: the potential role of serum hypoxia-inducible factor-1 $\alpha$ protein levels in obstructive sleep apnea-related cardiovascular disease. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 161-162.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?. <i>Kardiologia Polska</i> , 2020, 78, 482-483.	0.3	0
92	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , 2020, 19, 323-342.	0.8	15
93	Hydrocele in Pediatric Population. <i>Acta Medica (Hradec Kralove)</i> , 2020, 63, 57-62.	0.2	6
94	Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"? <i>Clinical and Molecular Hepatology</i> , 2020, 26, 582-583.	4.5	2
95	Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 922-922.	0.3	0
96	Inguinal hernia management in preterm infants: addressing current issues of interest. <i>Folia Medica Cracoviensia</i> , 2020, 60, 41-52.	0.3	0
97	Clinical image. Chylolympatic mesenteric cyst in a 3-month old infant. <i>Folia Medica Cracoviensia</i> , 2020, 60, 97-101.	0.3	1
98	Intramuscular hemangioma in the anterior scalene muscle in an infant boy: a case report. <i>Folia Medica Cracoviensia</i> , 2020, 60, 113-119.	0.3	0
99	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. <i>European Journal of Internal Medicine</i> , 2019, 69, 1-7.	1.0	5
100	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. <i>Journal of Sexual Medicine</i> , 2019, 16, 1199-1211.	0.3	5
101	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> . 2019, 158, 107927.	1.1	16
102	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , 2019, 24, 3638-3646.	0.9	10
103	Fusiform Cervical Mass in a 6-Year Old Boy; Do not Forget the Thymic Cyst. <i>Acta Medica (Hradec Kralove)</i> 2019, 62, 107-110.	0.2	1
104	Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension. <i>Current Pharmaceutical Design</i> , 2019, 24, 5500-5507.	0.9	4
105	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. <i>Current Clinical Pharmacology</i> , 2019, 13, 261-272.	0.2	13
106	Congenital Spigelian hernia and ipsilateral cryptorchidism: a new syndrome?. <i>Folia Medica Cracoviensia</i> , 2019, 59, 71-78.	0.3	3
107	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus ( <i>Diabetes Metab J</i> 2019;43:711-717). <i>Diabetes and Metabolism Journal</i> , 2019, 43, 906.	1.8	0
108	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 331-332.	4.5	0

#	ARTICLE	IF	CITATIONS
109	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 648-650.	0.3	0
110	Early diagnosis and surgical intervention untie the Gordian knot in newborns with colonic atresia: report of two cases and review of the literature. <i>Folia Medica Cracoviensia</i> , 2019, 59, 67-79.	0.3	0
111	Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. <i>Przegląd Gastroenterologiczny</i> , 2018, 13, 337-339.	0.3	0
112	Fountainâ€™s Sign as a Diagnostic Key in Acute Idiopathic Scrotal Edema: Case Report and Review of the Literature. <i>Acta Medica (Hradec Kralove)</i> , 2018, 61, 37-39.	0.2	4
113	Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 139-146.	0.2	16
114	Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2018, 18, 104-113.	0.2	2
115	Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) and its soluble in the plasma form (sTREM-1) as a diagnostic biomarker in neonatal sepsis. <i>Folia Medica Cracoviensia</i> , 2018, 58, 15-19.	0.3	7
116	A Bilateral, Non-syndromic, Type III Second Branchial Arch Sinus in a Neonate: a Case Report. <i>Acta Medica (Hradec Kralove)</i> , 2018, 61, 33-36.	0.2	0
117	Tunica Vaginalis Thickening, Hemorrhagic Infiltration and Inflammatory Changes in 8 Children with Primary Hydrocele; Reactive Mesothelial Hyperplasia? A Prospective Clinical Study. <i>Acta Medica (Hradec Kralove)</i> , 2018, 61, 41-46.	0.2	0
118	Diagnostic dilemma between sarcoidosis and primary Sjögren syndrome: mimicry, concomitance or coincidence? An up-to-date clinician's perspective. <i>Folia Medica Cracoviensia</i> , 2018, 58, 5-23.	0.3	0
119	Causes of secondary hypertension from a single center in Northern Greece; a retrospective clinical study. <i>Folia Medica Cracoviensia</i> , 2018, 58, 35-45.	0.3	1
120	Covered perforation of Meckel's diverticulum ulcer to transverse colon: highlighting the urgent intervention and the avoidance of a dramatic evolution (case report and literature review). <i>Folia Medica Cracoviensia</i> , 2018, 58, 83-87.	0.3	0
121	Cystic Lymphangioma of the Chest Wall in a 5-Year-Old Male Patient: A Rare and Atypical Localizationâ€™ A Case Report and Comprehensive Review of the Literature. <i>Case Reports in Pediatrics</i> , 2017, 2017, 1-6.	0.2	3
122	HSV-1 Encephalitis: High Index of Clinical Suspicion, Prompt Diagnosis, and Early Therapeutic Intervention Are the Triptych of Successâ€™ Report of Two Cases and Comprehensive Review of the Literature. <i>Case Reports in Medicine</i> , 2017, 2017, 1-6.	0.3	8
123	Rhabdomyolysis Induced by Coadministration of Fusidic Acid and Atorvastatin: A Case Report and Comprehensive Review of the Literature. <i>Case Reports in Nephrology</i> , 2017, 2017, 1-4.	0.2	0
124	Paraesophageal Hernia as a Cause of Chronic Asymptomatic Anemia in a 6 Years Old Boy; Case Report and Review of the Literature. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 76-81.	0.2	6
125	SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 167-170.	0.2	3
126	Amyandâ€™s Hernia: an Up-to-Date Review of the Literature. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 131-134.	0.2	28

#	ARTICLE	IF	CITATIONS
127	Transient testicular torsion: from early diagnosis to appropriate therapeutic intervention (a Tj ETQq1 1 0.784314 rgBT /Overlock 10 TFS	0.3	0
128	Acute primary mesenteroaxial gastric volvulus in a 6 years old child; the contribution of ultrasonographic findings to the prompt diagnosis (a case report and review of the literature). Folia Medica Cracoviensia, 2017, 57, 47-55.	0.3	1
129	Canaliform median raphe cysts (MRCs) lined by squamous epithelium in a 5 year old male patient; report of a rare case and comprehensive review of the literature. Folia Medica Cracoviensia, 2017, 57, 55-62.	0.3	2
130	HSV encephalitis: is the insight of the clinician still crucial for the outcome?. Folia Medica Cracoviensia, 2017, 57, 97-105.	0.3	0
131	Epididymal Adenomatoid Tumor: A Very Rare Paratesticular Tumor of Childhood. Case Reports in Medicine, 2016, 2016, 1-4.	0.3	6
132	Multiple Gastric Erosion Early after a 3â€%V Lithium Battery (CR2025) Ingestion in an 18-Month-Old Male Patient: Consideration about the Proper Time of Intervention. Case Reports in Pediatrics, 2016, 2016, 1-3.	0.2	3
133	Ulcerated Scrotal Hemangioma in an 18-Month-Old Male Patient: A Case Report and Review of the Literature. Case Reports in Urology, 2016, 2016, 1-4.	0.1	5
134	Dilatation of the Proximal Cystic Duct: Is It a Variant to â€œType VIâ€•Choledochal Cyst?. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, PD07-9.	0.8	3
135	Clinical Study of 23 Male Patients with Congenital Ventral Penile Angulation without Hypospadias. Acta Medica (Hradec Kralove), 2016, 59, 113-116.	0.2	0
136	Intraparenchymal Epididymal Cyst (IEC) 4 cm in Diameter in a 15-Year Old Male Patient; a Case Report and Review of the Literature. Acta Medica (Hradec Kralove), 2016, 59, 137-139.	0.2	1
137	Lower esophageal sphincter relaxation by administrating hyoscine-N-butylbromide for esophageal impaction by coin - shaped foreign bodies; prospective clinical study in pediatric population. Folia Medica Cracoviensia, 2016, 56, 21-29.	0.3	1
138	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. Journal of Diabetes and Metabolic Disorders, 0, , 1.	0.8	0
139	How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed. European Journal of Case Reports in Internal Medicine, 0, , .	0.2	0